Kumagai S, Koyama S, Nishikawa H (2021) Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer 21:181–197. https://doi.org/10.1038/s41568-020-00322-0

Article  CAS  PubMed  Google Scholar 

Lee HJ, Seo AN, Kim EJ et al (2015) Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer 112:103–111. https://doi.org/10.1038/bjc.2014.556

Article  CAS  PubMed  Google Scholar 

Liu X, Feng C, Liu J et al (2018) The importance of EGFR as a biomarker in molecular apocrine breast cancer. Hum Pathol 77:1–10. https://doi.org/10.1016/j.humpath.2018.01.016

Article  CAS  PubMed  Google Scholar 

Carlsson J, Wester K, De La Torre M et al (2015) EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides. Radiol Oncol 49:50–58. https://doi.org/10.2478/raon-2014-0015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hashimoto M, Fujita K, Tomiyama E et al (2023) Immunohistochemical analysis of HER2, EGFR, and nectin-4 expression in upper urinary tract urothelial carcinoma. Anticancer Res 43:167–174. https://doi.org/10.21873/anticanres.16146

Article  CAS  PubMed  Google Scholar 

Chan E, Alkhasawneh A, Duckworth LV et al (2016) EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. J Gastrointest Oncol 7:838–847. https://doi.org/10.21037/jgo.2016.06.09

Article  PubMed  PubMed Central  Google Scholar 

Ueda A, Takasawa A, Akimoto T et al (2017) Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix. PLoS ONE 12:e0184123. https://doi.org/10.1371/journal.pone.0184123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Day KC, Hiles GL, Kozminsky M et al (2017) HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res 77:74–85. https://doi.org/10.1158/0008-5472.CAN-16-1656

Article  CAS  PubMed  Google Scholar 

Carlsson J, Shen L, Xiang J et al (2013) Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncol Lett 5:208–214. https://doi.org/10.3892/ol.2012.996

Article  CAS  PubMed  Google Scholar 

Wang Z, Li H, Gou L et al (2023) Antibody–drug conjugates: recent advances in payloads. Acta Pharm Sin B 13:4025–4059. https://doi.org/10.1016/j.apsb.2023.06.015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shitara K, Bang Y-J, Iwasa S et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382:2419–2430. https://doi.org/10.1056/NEJMoa2004413

Article  CAS  PubMed  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125–1135. https://doi.org/10.1056/NEJMoa2035807

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tagawa ST, Balar AV, Petrylak DP et al (2021) TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 39:2474–2485. https://doi.org/10.1200/JCO.20.03489

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoury R, Saleh K, Khalife N et al (2023) Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci 24:9674. https://doi.org/10.3390/ijms24119674

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu Y, Wang Z, Wang Y (2024) Bispecific antibody drug conjugates: making 1+1>2. Acta Pharm Sinica B 14:1965–1986. https://doi.org/10.1016/j.apsb.2024.01.009

Article  CAS  Google Scholar 

Yonesaka K, Zejnullahu K, Okamoto I et al (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3:99ra86. https://doi.org/10.1126/scitranslmed.3002442

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartore-Bianchi A, Amatu A, Porcu L et al (2019) HER2 positivity predicts unresponsiveness to egfr-targeted treatment in metastatic colorectal cancer. Oncologist 24:1395–1402. https://doi.org/10.1634/theoncologist.2018-0785

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertotti A, Migliardi G, Galimi F et al (2011) A Molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1:508–523. https://doi.org/10.1158/2159-8290.CD-11-0109

Article  CAS  PubMed  Google Scholar 

Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101–126. https://doi.org/10.1038/s41573-022-00579-0

Article  CAS  PubMed  Google Scholar 

Yan M, Schwaederle M, Arguello D et al (2015) HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 34:157–164. https://doi.org/10.1007/s10555-015-9552-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dua R, Zhang J, Nhonthachit P et al (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-009-0592-x

Gupta A, Michelini F, Shao H et al (2024) EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med. https://doi.org/10.1016/j.xcrm.2024.101792

Article  PubMed  PubMed Central  Google Scholar 

Gandullo-Sánchez L, Pandiella A (2023) An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett 554:216024. https://doi.org/10.1016/j.canlet.2022.216024

Article  CAS  PubMed  Google Scholar 

Li G, Guo J, Shen B-Q et al (2018) Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther 17:1441–1453. https://doi.org/10.1158/1535-7163.MCT-17-0296

Article  CAS  PubMed  Google Scholar 

Zost SJ, Gilchuk P, Chen RE et al (2020) Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med 26:1422–1427. https://doi.org/10.1038/s41591-020-0998-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ku Z, Xie X, Lin J, et al (2022) Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth. bioRxiv 2022.02.01.478504. https://doi.org/10.1101/2022.02.01.478504

Godat B, Zimprich C, Dwight SJ et al (2016) Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. J Immunol Methods 431:11–21. https://doi.org/10.1016/j.jim.2016.02.001

Article  CAS  PubMed  Google Scholar 

Davidson M, Starling N (2016) Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. Onco Targets Ther 9:7235–7245. https://doi.org/10.2147/OTT.S100643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siena S, Di Bartolomeo M, Raghav K et al (2021) Trastuzumab deruxtecan (DS-8201) in patien